Literature DB >> 16908054

Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.

Katsuyuki Hamada1, Toshiro Shirakawa, Akinobu Gotoh, Jack A Roth, Michele Follen.   

Abstract

OBJECTIVE: In most cervical cancers, human papillomaviruses (HPVs) are identified. The E6 and E7 genes of HPVs encode proteins, that interfere with the function of the tumor suppressor proteins p53 and Rb. We are exploring the potential use of antisense HPV RNA transcripts for gene therapy for HPV-positive cervical cancers.
METHODS: Via a recombinant adenoviral vector, Ad5CMV-HPV 16 AS, we introduced the antisense RNA transcripts of the E6 and E7 genes of HPV type 16 into human cervical cancer SiHa cells harboring HPV 16. We then analyzed the effects of expression of these genes on cell and tumor growth.
RESULTS: HPV 16 E6/E7 antisense RNA was detected for 14 days in Ad5CMV-HPV 16 AS-infected cells. After infection, E6 and E7 protein expression was suppressed, and p53 and Rb protein expression increased. The Ad5CMV-HPV 16 AS-infected cells underwent apoptosis in vitro and in vivo. Cell growth and tumorigenicity were greatly suppressed. Ad5CMV-HPV 16 AS treatment significantly reduced the volumes of established subcutaneous tumors.
CONCLUSION: Transfection of cervical cancer cells with HPV 16 E6/E7 antisense RNA in a form such as Ad5CMV-HPV 16 AS might be a potentially useful approach to the therapy of HPV 16-positive cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908054     DOI: 10.1016/j.ygyno.2006.06.035

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma.

Authors:  Qian He; Shu-Qun Zhang; Yong-Lie Chu; Xiao-Li Jia; Xiang-Ling Wang
Journal:  Mol Biol Rep       Date:  2008-04-22       Impact factor: 2.316

Review 2.  Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer.

Authors:  Momeneh Ghanaat; Nasser Hashemi Goradel; Arash Arashkia; Nasim Ebrahimi; Sajjad Ghorghanlu; Ziba Veisi Malekshahi; Esmail Fattahi; Babak Negahdari; Hami Kaboosi
Journal:  Acta Pharmacol Sin       Date:  2021-02-25       Impact factor: 6.150

3.  The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.

Authors:  Erick de la Cruz-Hernández; Enrique Pérez-Cárdenas; Adriana Contreras-Paredes; David Cantú; Alejandro Mohar; Marcela Lizano; Alfonso Dueñas-González
Journal:  Virol J       Date:  2007-02-26       Impact factor: 4.099

4.  Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.

Authors:  Marie-Laure Plissonnier; Sylvie Fauconnet; Hugues Bittard; Christiane Mougin; Jean Rommelaere; Isabelle Lascombe
Journal:  Oncotarget       Date:  2017-11-22

Review 5.  Biological and clinical aspects of HPV-related cancers.

Authors:  Klaudia Anna Szymonowicz; Junjie Chen
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

6.  Establishment and characterization of three new human breast cancer cell lines derived from Chinese breast cancer tissues.

Authors:  Chao Shen; Meijia Gu; Dan Liang; Lixia Miao; Liu Hu; Congyi Zheng; Jiakuan Chen
Journal:  Cancer Cell Int       Date:  2009-01-02       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.